Skip to main content

Table 8 Clinical and hemodynamic effect of BPA treatment in 24 CTEPH patients

From: Bilateral versus unilateral balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension

  24 CTEPH patients p
Before BPA After BPA
Patient characteristics
 Age (years) 59 ± 10
 Female (%) 18 (75%)
 Number of BPA sessions/patient 3 (2,4)
 Duration to follow-up (days) 115 (81, 177)
 PAH targeted therapy (%) 11 (45.8%)  
Hemodynamics
 Heart rate 79.8 ± 15.3 69.5 ± 10.1 0.009
 Mean RAP (mmHg) 7.9 ± 4.0 5.5 ± 3.4 0.062
 Systolic PAP (mmHg) 70.8 ± 25.0 50.3 ± 14.2 0.001
 Diastolic PAP (mmHg) 23.5 ± 9.1 15.8 ± 6.0 0.001
 Mean PAP (mmHg) 40.6 ± 13.8 28.5 ± 8.0 0.001
 PVR (Wood unit) 8.0 (3.7,17.0) 4.0 (2.9, 5.4) 0.007
 Cardiac output (L/min) 3.5 (2.6, 5.4) 4.7 (3.7, 5.8) 0.017
 Cardiac index (L/min/m2) 2.2 (1.8, 3.4) 2.9 (2.5, 3.5) 0.044
 PASO2 (%) 64.1 ± 9.5 68.7 ± 7.2 0.068
 MVSO2 (%) 93.7 ± 3.4 95.2 ± 3.0 0.116
 NT-proBNP (pg/ml) 171.0 (71.5, 1569.0) 50.6 (26.5, 113.4) 0.002
Exercise capacity
 WHO functional class (I–II/III–IV, %) 50.0%/50.0% 95.8%/4.2% < 0.001
 Absolute change of 6MWD (meters) 88.0 ± 55.5 < 0.001
  1. Continuous variables are expressed as mean ± standard deviation or median and interquartile range according to variable distribution
  2. CTEPH chronic thromboembolic pulmonary hypertension, BPA balloon pulmonary angioplasty, RAP right atrium pressure, PAP pulmonary artery pressure, PVR pulmonary vascular resistance, PASO2 pulmonary arterial oxygen saturation, MVSO2 mixed venous oxygen saturation, NT-proBNP N-terminal pro-B-type natriuretic peptide, WHO World Health Organization, 6MWD 6-min walk distance